Everest Medicines Ltd. (1952) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1952 Analyst Ratings

Currently, no data available

Based on NaN analysts giving stock ratings to

Everest

Medicines Ltd.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1952 Stock 12 Month Forecast

There Are No Analyst Ratings for HK:1952 In The Last 3 Months.

Highest Price Target―

Average Price Target―

Lowest Price Target―

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

1952 Financial Forecast

1952 Earnings Forecast

Next quarter’s earnings estimate for 1952 is HK$0.05 with a range of HK$0.05 to HK$0.05. The previous quarter’s EPS was -HK$0.84. 1952 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1952 has Outperformed its overall industry.

1952 Sales Forecast

Next quarter’s sales forecast for 1952 is HK$1.37B with a range of HK$1.37B to HK$1.37B. The previous quarter’s sales results were HK$479.20M. 1952 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1952 has Performed in-line its overall industry.

Detailed List of Analyst Forecasts

Jack Lin

Morgan Stanley

HK$40→HK$55

Hold

6.80%

Upside

Reiterated

09/22/25

Everest Medicines Ltd. (1952) Gets a Hold from Morgan StanleyMorgan Stanley analyst Jack Lin raised the price target on Everest Medicines Ltd (1952:HK) to HK$55.00 (from HK$40.00) while maintaining a Equalweight rating.

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$73.6

Buy

42.91%

Upside

Reiterated

09/05/25

Unknown Analyst

Citi

Not Ranked

Citi

HK$65

Hold

26.21%

Upside

Reiterated

09/01/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$84

Buy

63.11%

Upside

Reiterated

09/01/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$88

Buy

70.87%

Upside

Reiterated

09/01/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$72.5

Buy

40.78%

Upside

Reiterated

08/05/25

Ziyi Chen

Goldman Sachs

HK$49.11→HK$64.27

Hold

24.80%

Upside

Reiterated

07/09/25

Everest Medicines Ltd. (1952) Receives a Hold from Goldman Sachs

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$72.5

Buy

40.78%

Upside

Reiterated

07/02/25

Unknown Analyst

Founder Securities Co.

Not Ranked

Founder Securities Co.

HK$68.8

Buy

33.59%

Upside

Reiterated

05/23/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$62.1

Buy

20.58%

Upside

Reiterated

05/09/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$65

Buy

26.21%

Upside

Reiterated

03/27/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jack Lin

Morgan Stanley

HK$40→HK$55

Hold

6.80%

Upside

Reiterated

09/22/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$73.6

Buy

42.91%

Upside

Reiterated

09/05/25

Unknown Analyst

Citi

Not Ranked

Citi

HK$65

Hold

26.21%

Upside

Reiterated

09/01/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$84

Buy

63.11%

Upside

Reiterated

09/01/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$88

Buy

70.87%

Upside

Reiterated

09/01/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$72.5

Buy

40.78%

Upside

Reiterated

08/05/25

Ziyi Chen

Goldman Sachs

HK$49.11→HK$64.27

Hold

24.80%

Upside

Reiterated

07/09/25

Everest Medicines Ltd. (1952) Receives a Hold from Goldman Sachs

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$72.5

Buy

40.78%

Upside

Reiterated

07/02/25

Unknown Analyst

Founder Securities Co.

Not Ranked

Founder Securities Co.

HK$68.8

Buy

33.59%

Upside

Reiterated

05/23/25

Unknown Analyst

TFI Asset Management

Not Ranked

TFI Asset Management

HK$62.1

Buy

20.58%

Upside

Reiterated

05/09/25

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$65

Buy

26.21%

Upside

Reiterated

03/27/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Everest Medicines Ltd.

1 Month

xxx

Success Rate

0/0 ratings generated profit

Average Return

0.00%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in - of your transactions generating a profit, with an average return of 0.00% per trade.

3 Months

xxx

Success Rate

0/0 ratings generated profit

Average Return

0.00%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in - of your transactions generating a profit, with an average return of 0.00% per trade.

1 Year

Unknown AnalystTFI Asset Management

Not Ranked

Success Rate

0/0 ratings generated profit

Average Return

0.00%

reiterated a buy rating 4 months ago

Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.

2 Years

xxx

Success Rate

0/0 ratings generated profit

Average Return

0.00%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in - of your transactions generating a profit, with an average return of 0.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1952 Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1952 has received 3 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 1952 average Analyst price target in the past 3 months is ―.

Each month's total comprises the sum of three months' worth of ratings.

1952 Stock Forecast FAQ

What is HK:1952’s average 12-month price target, according to analysts?

Currently, no data Available

What is HK:1952’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for HK:1952, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Everest Medicines Ltd. a Buy, Sell or Hold?

Currently, no data Available

What is Everest Medicines Ltd.’s share price target?

Currently, no data Available

What do analysts say about Everest Medicines Ltd.?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of Everest Medicines Ltd.?

To buy shares of HK:1952, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Everest Medicines Ltd. (1952) Stock Forecast & Price Target

1952 Analyst Ratings

1952 Stock 12 Month Forecast

1952 Financial Forecast

1952 Earnings Forecast

1952 Sales Forecast

Detailed List of Analyst Forecasts​

Best Analysts Covering Everest Medicines Ltd.

1952 Analyst Recommendation Trends

1952 Stock Forecast FAQ

Detailed List of Analyst Forecasts